

Comparative Tolerability and Harms of Individual Stati

Circulation: Cardiovascular Quality and Outcomes
6, 390-399

DOI: [10.1161/circoutcomes.111.000071](https://doi.org/10.1161/circoutcomes.111.000071)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Searching the place of pitavastatin in the current treatment of patients with dyslipidemia. Expert Review of Cardiovascular Therapy, 2013, 11, 1597-1612.	0.6	4
2	Pharmacometabolomics of Statin Response. Clinical Pharmacology and Therapeutics, 2013, 94, 562-565.	2.3	44
3	Diagnosis, Prevention, and Management of Statin Adverse Effects and Intolerance: Canadian Working Group Consensus Update. Canadian Journal of Cardiology, 2013, 29, 1553-1568.	0.8	153
4	A Prospective Stratified Case-Cohort Study on Statins and Multiple Adverse Events in Japan. PLoS ONE, 2014, 9, e96919.	1.1	4
5	Unanswered questions about higher potency statins and the risk of new diabetes. BMJ, The, 2014, 349, g4876-g4876.	3.0	1
6	Author's reply to Phillips and Brugts. BMJ, The, 2014, 349, g4890-g4890.	3.0	0
7	Characterization of diabetes risk factors in patients prescribed chronic statin therapy. Therapeutic Advances in Chronic Disease, 2014, 5, 206-211.	1.1	1
8	Combined Administration of RG7652, a Recombinant Human Monoclonal Antibody Against PCSK9, and Atorvastatin Does Not Result in Reduction of Immune Function. Toxicological Sciences, 2014, 140, 470-480.	1.4	6
9	Industry sponsorship bias in research findings: a network meta-analysis of LDL cholesterol reduction in randomised trials of statins. BMJ, The, 2014, 349, g5741-g5741.	3.0	55
10	Nonfatal Outcomes in the Primary Prevention of Atherosclerotic Cardiovascular Disease. Circulation: Cardiovascular Quality and Outcomes, 2014, 7, 481-485.	0.9	3
11	Pharmacology of statins: A brief overview. NursePrescribing, 2014, 12, 451-456.	0.1	2
12	<i>Circulation: Cardiovascular Quality and Outcomes</i>. Circulation, 2014, 129, .	1.6	1
13	Do the immunosuppressive effects of statins increase ^Merkel cell carcinoma risk?. International Journal of Dermatology, 2014, 53, e406-9.	0.5	4
14	Predictors of type 2 diabetes in a nationally representative sample of adults with psychosis. World Psychiatry, 2014, 13, 176-183.	4.8	30
15	Canadian Cardiovascular Society Position Statement on Familial Hypercholesterolemia. Canadian Journal of Cardiology, 2014, 30, 1471-1481.	0.8	93
16	Pharmacogenomics of statin therapy. Current Opinion in Lipidology, 2014, 25, 438-445.	1.2	15
17	An Update on the Benefits and Risks of Rosuvastatin Therapy. Postgraduate Medicine, 2014, 126, 7-17.	0.9	14
18	The Incidence of Kidney Injury for Patients Treated With a High-Potency Versus Moderate-Potency Statin Regimen After an Acute Coronary Syndrome. Journal of the American Heart Association, 2014, 3, e000784.	1.6	12

#	ARTICLE	IF	CITATIONS
19	Statin intolerance: diagnosis, treatment and alternative therapies. <i>Clinical Lipidology</i> , 2014, 9, 355-367.	0.4	3
20	How Low an LDL-C Should We Go With Statin Therapy?. <i>Current Atherosclerosis Reports</i> , 2014, 16, 388.	2.0	7
21	Treatment of Cholesterol in the Elderly: Statins and Beyond. <i>Current Atherosclerosis Reports</i> , 2014, 16, 385.	2.0	8
22	Long-term efficacy and safety of statin treatment beyond six years: A meta-analysis of randomized controlled trials with extended follow-up. <i>Pharmacological Research</i> , 2014, 81, 64-73.	3.1	23
23	Addressing Statin Adverse Effects in the Clinic. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2014, 19, 533-542.	1.0	22
24	Evidence supporting primary prevention of cardiovascular diseases with statins: Gaps between updated clinical results and actual practice. <i>Archives of Cardiovascular Diseases</i> , 2014, 107, 188-200.	0.7	15
25	A Meta-Analysis of Randomized Head-to-Head Trials for Effects of Rosuvastatin Versus Atorvastatin on Apolipoprotein Profiles. <i>American Journal of Cardiology</i> , 2014, 113, 292-301.	0.7	14
26	The strategies to control prostate cancer by chemoprevention approaches. <i>Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis</i> , 2014, 760, 1-15.	0.4	30
27	Efficacy and Safety of Pitavastatin Versus Simvastatin: A Meta-Analysis of Randomized Controlled Trials. <i>Clinical Drug Investigation</i> , 2014, 34, 599-608.	1.1	8
28	The 2013 ACC/AHA cardiovascular prevention guidelines improve alignment of statin therapy with coronary atherosclerosis as detected by coronary computed tomography angiography. <i>Atherosclerosis</i> , 2014, 237, 314-318.	0.4	20
29	Evidence-Based Prescribing. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2014, 7, 787-792.	0.9	27
30	Ability of Low Antihypertensive Medication Adherence to Predict Statin Discontinuation and Low Statin Adherence in Patients Initiating Treatment After a Coronary Event. <i>American Journal of Cardiology</i> , 2014, 114, 826-831.	0.7	31
31	Unintended effects of statins from observational studies in the general population: systematic review and meta-analysis. <i>BMC Medicine</i> , 2014, 12, 51.	2.3	149
32	Statin treatment and new-onset diabetes: A review of proposed mechanisms. <i>Metabolism: Clinical and Experimental</i> , 2014, 63, 735-745.	1.5	186
33	NLA Task Force on Statin Safety - 2014 update. <i>Journal of Clinical Lipidology</i> , 2014, 8, S1-S4.	0.6	114
34	Statin-Associated Incident Diabetes: A Literature Review. <i>The Consultant Pharmacist</i> , 2014, 29, 317-334.	0.4	22
36	Management of Dyslipidemia for Cardiovascular Disease Risk Reduction: Synopsis of the 2014 U.S. Department of Veterans Affairs and U.S. Department of Defense Clinical Practice Guideline. <i>Annals of Internal Medicine</i> , 2015, 163, 291-297.	2.0	100
37	Evaluation of the Potential Role of Alirocumab in the Management of Hypercholesterolemia in Patients with High-Risk Cardiovascular Disease. <i>Pharmacotherapy</i> , 2015, 35, 771-779.	1.2	4

#	ARTICLE	IF	CITATIONS
38	Prioritizing health outcomes in a limited world. <i>Current Opinion in Lipidology</i> , 2015, 26, 188-194.	1.2	2
39	SLCO1B1 c.388A>G Polymorphism Is Associated with HDL-C Levels in Response to Atorvastatin in Chilean Individuals. <i>International Journal of Molecular Sciences</i> , 2015, 16, 20609-20619.	1.8	20
40	Treatment Options for Statin-Associated Muscle Symptoms. <i>Deutsches A&#x0308;rzteblatt International</i> , 2015, 112, 748-55.	0.6	65
41	Therapeutic Options: Lifestyle Measures and Pharmacological Approaches. , 2015, , 417-431.		0
42	Applying Multiple Criteria Decision Analysis to Comparative Benefit-Risk Assessment. <i>Medical Decision Making</i> , 2015, 35, 859-871.	1.2	44
43	Evaluating the Phase II drugs currently under investigation for diabetic neuropathy. <i>Expert Opinion on Investigational Drugs</i> , 2015, 24, 1-15.	1.9	4
44	Could changes in adiponectin drive the effect of statins on the risk of new-onset diabetes? The case of pitavastatin. <i>Atherosclerosis Supplements</i> , 2015, 16, 1-27.	1.2	45
45	Do Statins Impair Cognition? A Systematic Review and Meta-Analysis of Randomized Controlled Trials. <i>Journal of General Internal Medicine</i> , 2015, 30, 348-358.	1.3	176
46	Present status of statin therapy. <i>Trends in Cardiovascular Medicine</i> , 2015, 25, 216-225.	2.3	17
50	Sphingosine-1-Phosphate Receptor Subtype 2 Signaling in Endothelial Senescence-Associated Functional Impairments and Inflammation. <i>Current Atherosclerosis Reports</i> , 2015, 17, 504.	2.0	17
51	Effects of Statins on Hospital Length of Stay and All-Cause Readmissions Among Hospitalized Patients With a Primary Diagnosis of Sepsis. <i>Annals of Pharmacotherapy</i> , 2015, 49, 1273-1283.	0.9	5
52	Statin action favors normalization of the plasma lipidome in the atherogenic mixed dyslipidemia of MetS: potential relevance to statin-associated dysglycemia. <i>Journal of Lipid Research</i> , 2015, 56, 2381-2392.	2.0	47
53	A Review of Statin Use and Prostate Cancer. <i>Current Atherosclerosis Reports</i> , 2015, 17, 474.	2.0	13
54	Management of Dyslipidemia for Cardiovascular Disease Risk Reduction. <i>Annals of Internal Medicine</i> , 2016, 164, 509.	2.0	12
55	Statin myopathy. <i>Current Opinion in Cardiology</i> , 2016, 31, 417-425.	0.8	7
56	Statin use and the risk of developing diabetes: a network meta-analysis. <i>Pharmacoepidemiology and Drug Safety</i> , 2016, 25, 1131-1149.	0.9	97
57	Statin-induced liver injury in an area endemic for hepatitis B virus infection: risk factors and outcome analysis. <i>British Journal of Clinical Pharmacology</i> , 2016, 82, 823-830.	1.1	6
58	Drug-induced Diabetes Mellitus: Evidence for Statins and Other Drugs Affecting Glucose Metabolism. <i>Clinical Pharmacology and Therapeutics</i> , 2016, 99, 390-400.	2.3	30

#	ARTICLE	IF	CITATIONS
60	Antiplatelet regimens in the long-term secondary prevention of transient ischaemic attack and ischaemic stroke: an updated network meta-analysis. <i>BMJ Open</i> , 2016, 6, e009013.	0.8	44
61	Clinical Profile of Statin Intolerance in the Phase 3 GAUSS-2 Study. <i>Cardiovascular Drugs and Therapy</i> , 2016, 30, 297-304.	1.3	23
62	Additional therapy for cholesterol lowering in ezetimibe-treated, statin-intolerant patients in clinical practice: results from an internal audit of a university lipid clinic. <i>Current Medical Research and Opinion</i> , 2016, 32, 1633-1638.	0.9	17
64	Statin withdrawal in people with dementia. <i>The Cochrane Library</i> , 2016, 9, CD012050.	1.5	5
65	2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. <i>Atherosclerosis</i> , 2016, 253, 281-344.	0.4	1,189
66	Communication of Treatment Rankings Obtained From Network Meta-Analysis Using Data Visualization. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2016, 9, 605-608.	0.9	4
67	Effect on Fasting Serum Glucose Levels of Adding Ezetimibe to Statins in Patients With Nondiabetic Hypercholesterolemia. <i>American Journal of Cardiology</i> , 2016, 118, 1812-1820.	0.7	7
68	Registered Randomized Trials Comparing Generic and Brand-Name Drugs: A Survey. <i>Mayo Clinic Proceedings</i> , 2016, 91, 1021-1034.	1.4	9
69	Drugs for hypercholesterolaemia – from statins to pro-protein convertase subtilisin kexin 9 (PCSK9) inhibition. <i>Clinical Medicine</i> , 2016, 16, 353-357.	0.8	8
70	Pharmacologically effective red yeast rice preparations marketed as dietary supplements illustrated by a case report. <i>Drug Testing and Analysis</i> , 2016, 8, 315-318.	1.6	18
71	2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. <i>European Heart Journal</i> , 2016, 37, 2999-3058.	1.0	2,393
72	PCSK9 Inhibitors. <i>Journal of Pharmacy Technology</i> , 2016, 32, 201-209.	0.5	1
73	Severity of statin-induced adverse effects on muscle and associated conditions: data from the DAMA study. <i>Expert Opinion on Drug Safety</i> , 2016, 15, 1583-1587.	1.0	19
74	Interpretation of the evidence for the efficacy and safety of statin therapy. <i>Lancet</i> , 2016, 388, 2532-2561.	6.3	1,399
75	Current and Emerging Uses of Statins in Clinical Therapeutics: A Review. <i>Lipid Insights</i> , 2016, 9, LPI.S37450.	1.0	115
76	Low use of statins for secondary prevention in primary care: a survey in a northern Swedish population. <i>BMC Family Practice</i> , 2016, 17, 110.	2.9	12
77	Statins and risk for new-onset diabetes mellitus. <i>Medicine (United States)</i> , 2016, 95, e5429.	0.4	24
78	Development and Validation of Algorithms to Identify Statin Intolerance in a US Administrative Database. <i>Value in Health</i> , 2016, 19, 852-860.	0.1	15

#	ARTICLE	IF	CITATIONS
79	Use of Statins and the Risk of Incident Diabetes: A Retrospective Cohort Study. <i>American Journal of Cardiovascular Drugs</i> , 2016, 16, 377-390.	1.0	17
80	Statins and new-onset diabetes mellitus – a risk lacking in familial hypercholesterolaemia. <i>Journal of Internal Medicine</i> , 2016, 279, 358-361.	2.7	12
81	Pharmacological inhibition of lipid droplet formation enhances the effectiveness of curcumin in glioblastoma. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2016, 100, 66-76.	2.0	44
82	Statin therapy across the lifespan: evidence in major age groups. <i>Expert Review of Cardiovascular Therapy</i> , 2016, 14, 341-366.	0.6	12
83	Imbalanced insulin action in chronic over nutrition: Clinical harm, molecular mechanisms, and a way forward. <i>Atherosclerosis</i> , 2016, 247, 225-282.	0.4	67
84	Safety Profile of Atorvastatin 80mg: A Meta-Analysis of 17 Randomized Controlled Trials in 21,910 Participants. <i>Drug Safety</i> , 2016, 39, 409-419.	1.4	10
85	Approach to Statin Use in 2016: an Update. <i>Current Atherosclerosis Reports</i> , 2016, 18, 20.	2.0	26
86	Effects of LEP G2548A and LEPR Q223R Polymorphisms on Serum Lipids and Response to Simvastatin Treatment in Chinese Patients With Primary Hyperlipidemia. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2017, 23, 336-344.	0.7	4
87	Adverse reactions to dietary supplements containing red yeast rice: assessment of cases from the Italian surveillance system. <i>British Journal of Clinical Pharmacology</i> , 2017, 83, 894-908.	1.1	67
88	Assessing potential population impact of statin treatment for primary prevention of atherosclerotic cardiovascular diseases in the USA: population-based modelling study. <i>BMJ Open</i> , 2017, 7, e011684.	0.8	21
89	Technological advances and proteomic applications in drug discovery and target deconvolution: identification of the pleiotropic effects of statins. <i>Drug Discovery Today</i> , 2017, 22, 848-869.	3.2	23
90	Statin Use Correlates with Reduced Risk of Pyogenic Liver Abscess: A Population-Based Case-Control Study. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2017, 121, 144-149.	1.2	15
91	Adverse events associated with unblinded, but not with blinded, statin therapy in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA): a randomised double-blind placebo-controlled trial and its non-randomised non-blind extension phase. <i>Lancet</i> , The, 2017, 389, 2473-2481.	6.3	279
92	Anti-cholesterol activity test of tanjung (<i>Mimusops elengi</i> L.) leaf extract in the water using in vivo method in mice (<i>Mus musculus</i> L.) DDY-strain. , 2017, , .		6
93	Influence of route of administration/drug formulation and other factors on adherence to treatment in rheumatoid arthritis (pain related) and dyslipidemia (non-pain related). <i>Current Medical Research and Opinion</i> , 2017, 33, 1231-1246.	0.9	11
94	Use of Lipid-modifying Therapy and LDL-C Goal Attainment in a High-Cardiovascular-Risk Population in the Netherlands. <i>Clinical Therapeutics</i> , 2017, 39, 819-827.e1.	1.1	38
95	Statins and mortality: the untold story. <i>British Journal of Clinical Pharmacology</i> , 2017, 83, 938-941.	1.1	4
96	The challenges of proprotein convertase subtilisin/kexin-9 inhibitors for lipid guidelines and models of care. <i>Current Opinion in Lipidology</i> , 2017, 28, 470-476.	1.2	1

#	ARTICLE	IF	CITATIONS
97	Statins and venous thromboembolism: do they represent a viable therapeutic agent?. Expert Review of Cardiovascular Therapy, 2017, 15, 629-637.	0.6	7
98	Sphingolipids and phospholipids in insulin resistance and related metabolic disorders. Nature Reviews Endocrinology, 2017, 13, 79-91.	4.3	313
99	Guideline-based statin/lipid-lowering therapy eligibility for primary prevention and accuracy of coronary artery calcium and clinical cardiovascular events: The Multi-Ethnic Study of Atherosclerosis (MESA). Clinical Cardiology, 2017, 40, 163-169.	0.7	7
100	Identification of Patients with Statin Intolerance in a Managed Care Plan: A Comparison of 2 Claims-Based Algorithms. Journal of Managed Care & Specialty Pharmacy, 2017, 23, 926-934.	0.5	2
101	Statins, Muscle Disease and Mitochondria. Journal of Clinical Medicine, 2017, 6, 75.	1.0	61
102	Pharmacogenetic Foundations of Therapeutic Efficacy and Adverse Events of Statins. International Journal of Molecular Sciences, 2017, 18, 104.	1.8	31
103	Multiple criteria decision analysis in the context of health technology assessment: a simulation exercise on metastatic colorectal cancer with multiple stakeholders in the English setting. BMC Medical Informatics and Decision Making, 2017, 17, 149.	1.5	23
104	Statin utilization and lipid goal attainment in high or very-high cardiovascular risk patients: Insights from Italian general practice. Atherosclerosis, 2018, 271, 120-127.	0.4	31
105	Patterns of statin use and long-term adherence and persistence among older adults with diabetes. Journal of Diabetes, 2018, 10, 699-707.	0.8	32
106	Dose-Dependent Effects of Statins for Patients with Aneurysmal Subarachnoid Hemorrhage: Meta-Regression Analysis. World Neurosurgery, 2018, 113, 153-162.	0.7	5
108	Atorvastatin impaired glucose metabolism in C2C12 cells partly via inhibiting cholesterol-dependent glucose transporter 4 translocation. Biochemical Pharmacology, 2018, 150, 108-119.	2.0	24
109	Adverse effects of statin therapy: perception vs. the evidence – focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract. European Heart Journal, 2018, 39, 2526-2539.	1.0	262
110	Temporal Trends of High-Intensity Statin Therapy Among Veterans Treated With Percutaneous Coronary Intervention. Journal of the American Heart Association, 2018, 7, .	1.6	9
111	Preventive effect of goby fish protein hydrolysates on hyperlipidemia and cardiovascular disease in Wistar rats fed a high-fat/fructose diet. RSC Advances, 2018, 8, 9383-9393.	1.7	18
112	The effect of lipophilicity and dose on the frequency of statin-associated muscle symptoms: A systematic review and meta-analysis. Pharmacological Research, 2018, 128, 264-273.	3.1	18
113	Comparative effect of statins on the risk of incident Alzheimer disease. Neurology, 2018, 90, e179-e187.	1.5	32
114	Is Atorvastatin Associated with New Onset Diabetes or Deterioration of Glycemic Control? Systematic Review Using Data from 1.9 Million Patients. International Journal of Endocrinology, 2018, 2018, 1-17.	0.6	20
115	Effect of statins on fasting glucose in non-diabetic individuals: nationwide population-based health examination in Korea. Cardiovascular Diabetology, 2018, 17, 155.	2.7	34

#	ARTICLE	IF	CITATIONS
116	Statins and Multiple Noncardiovascular Outcomes. <i>Annals of Internal Medicine</i> , 2018, 169, 543.	2.0	68
117	Evaluating the Benefits of New Drugs in Health Technology Assessment Using Multiple Criteria Decision Analysis: A Case Study on Metastatic Prostate Cancer With the Dental and Pharmaceuticals Benefits Agency (TLV) in Sweden. <i>MDM Policy and Practice</i> , 2018, 3, 238146831879621.	0.5	5
118	Effects of Delivering <i>SLCO1B1</i> Pharmacogenetic Information in Randomized Trial and Observational Settings. <i>Circulation Genomic and Precision Medicine</i> , 2018, 11, e002228.	1.6	40
119	High-potency statins but not all statins decrease the risk of new-onset osteoporotic fractures: a nationwide population-based longitudinal cohort study. <i>Clinical Epidemiology</i> , 2018, Volume 10, 159-165.	1.5	22
120	Meta-Analysis of Usefulness of Psyllium Fiber as Adjuvant Antilipid Therapy to Enhance Cholesterol Lowering Efficacy of Statins. <i>American Journal of Cardiology</i> , 2018, 122, 1169-1174.	0.7	32
121	Hyperlipidemia: Management with Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors. <i>Journal of the American Board of Family Medicine</i> , 2018, 31, 628-634.	0.8	11
122	Should statin guidelines consider patient preferences? Eliciting preferences of benefit and harm outcomes of statins for primary prevention of cardiovascular disease in the sub-Saharan African and European contexts. <i>BMC Cardiovascular Disorders</i> , 2018, 18, 97.	0.7	21
124	Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: A randomized, placebo-controlled study. <i>Atherosclerosis</i> , 2018, 277, 195-203.	0.4	298
125	Treatment with Statins in Elderly Patients. <i>Medicina (Lithuania)</i> , 2019, 55, 721.	0.8	47
126	Does Early Graft Patency Benefit from Perioperative Statin Therapy? A Propensity Score-Matched Study of Patients Undergoing Off-Pump Coronary Artery Bypass Surgery. <i>Cardiovascular Therapeutics</i> , 2019, 1-9.	1.1	1
127	2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. <i>Atherosclerosis</i> , 2019, 290, 140-205.	0.4	1,753
128	The cardioprotective properties and the involved mechanisms of NaoXinTong Capsule. <i>Pharmacological Research</i> , 2019, 141, 409-417.	3.1	49
129	Biochemical markers of muscle damage and high serum concentration of creatine kinase in patients on statin therapy. <i>Biomarkers in Medicine</i> , 2019, 13, 619-626.	0.6	11
130	Pharmacokinetic Drug Interaction Between Rosuvastatin and Tanjin in Healthy Volunteers and Rats. <i>Yonago Acta Medica</i> , 2019, 62, 077-084.	0.3	6
131	Current pharmacotherapeutic options for primary dyslipidemia in adults. <i>Expert Opinion on Pharmacotherapy</i> , 2019, 20, 1277-1288.	0.9	18
132	Risk of Statin-Induced Hypertransaminasemia. <i>Mayo Clinic Proceedings Innovations, Quality & Outcomes</i> , 2019, 3, 131-140.	1.2	5
133	Combining Multiple Treatment Comparisons with Personalized Patient Preferences: A Randomized Trial of an Interactive Platform for Statin Treatment Selection. <i>Medical Decision Making</i> , 2019, 39, 264-277.	1.2	11
134	Trends and variations in outpatient coprescribing of simvastatin or atorvastatin with potentially interacting drugs in Thailand. <i>Therapeutic Advances in Drug Safety</i> , 2019, 10, 204209861882050.	1.0	2

#	ARTICLE	IF	CITATIONS
135	Emerging drugs for the treatment of hypercholesterolemia. <i>Expert Opinion on Emerging Drugs</i> , 2019, 24, 63-69.	1.0	16
136	Harnessing nucleic acid-based therapeutics for atherosclerotic cardiovascular disease: state of the art. <i>Drug Discovery Today</i> , 2019, 24, 1116-1131.	3.2	18
137	Cardiovascular events, diabetes and guidelines: the virtue of simplicity. <i>Cardiovascular Diabetology</i> , 2019, 18, 42.	2.7	19
138	Preparation of a carboxymethylcellulose-iron composite for uptake of atorvastatin in water. <i>International Journal of Biological Macromolecules</i> , 2019, 132, 244-253.	3.6	134
139	Simvastatin as a neuroprotective treatment for Parkinson's disease (PD STAT): protocol for a double-blind, randomised, placebo-controlled futility study. <i>BMJ Open</i> , 2019, 9, e029740.	0.8	26
140	A prospective study of hepatic safety of statins used in very elderly patients. <i>BMC Geriatrics</i> , 2019, 19, 352.	1.1	6
141	Comprehensive evaluation of effects and safety of statin on the progression of liver cirrhosis: a systematic review and meta-analysis. <i>BMC Gastroenterology</i> , 2019, 19, 231.	0.8	32
142	State of the Art Comprehensive Review of Individual Statins, Their Differences, Pharmacology, and Clinical Implications. <i>Cardiovascular Drugs and Therapy</i> , 2019, 33, 625-639.	1.3	27
143	High exposure to statins decrease the risk of new-onset dementia. <i>Medicine (United States)</i> , 2019, 98, e16931.	0.4	11
144	The Association between Genetic Polymorphisms and Simvastatin-Induced Myopathy: A Narrative Synthesis of Evidence. <i>Drug Research</i> , 2019, 69, 185-193.	0.7	1
145	Pharmacological Options in Atherosclerosis: A Review of the Existing Evidence. <i>Cardiology and Therapy</i> , 2019, 8, 5-20.	1.1	17
146	Comparative effectiveness and safety of statins as a class and of specific statins for primary prevention of cardiovascular disease: A systematic review, meta-analysis, and network meta-analysis of randomized trials with 94,283 participants. <i>American Heart Journal</i> , 2019, 210, 18-28.	1.2	102
147	Finding the Balance Between Benefits and Harms When Using Statins for Primary Prevention of Cardiovascular Disease. <i>Annals of Internal Medicine</i> , 2019, 170, 1.	2.0	126
149	Statin Intolerance Clinical Guide 2018. <i>Journal of Atherosclerosis and Thrombosis</i> , 2020, 27, 375-396.	0.9	17
150	2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. <i>European Heart Journal</i> , 2020, 41, 111-188.	1.0	4,871
151	A Randomized Trial of Alerting to Hypocholesterolemia Results of the Low Indexes of Metabolism Intervention Trial-C (LIMIT-C). <i>Journal of the American Medical Directors Association</i> , 2020, 21, 410-414.	1.2	0
152	Intensive LDL cholesterol-lowering treatment beyond current recommendations for the prevention of major vascular events: a systematic review and meta-analysis of randomised trials including 327,037 participants. <i>Lancet Diabetes and Endocrinology</i> , 2020, 8, 36-49.	5.5	115
153	<i>Pinus thunbergii</i> PARL leaf protects against alcohol-induced liver disease by enhancing antioxidant defense mechanism in BALB/c mice. <i>Journal of Functional Foods</i> , 2020, 73, 104116.	1.6	14

#	ARTICLE	IF	CITATIONS
154	Iranian general populations' and health care providers' preferences for benefits and harms of statin therapy for primary prevention of cardiovascular disease. <i>BMC Medical Informatics and Decision Making</i> , 2020, 20, 288.	1.5	1
155	Protective Effects of Polyphenols against Ischemia/Reperfusion Injury. <i>Molecules</i> , 2020, 25, 3469.	1.7	25
156	Statin intolerance: an updated, narrative review mainly focusing on muscle adverse effects. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2020, 16, 837-851.	1.5	8
157	Global variation of risk thresholds for initiating statins for primary prevention of cardiovascular disease: a benefit-harm balance modelling study. <i>BMC Cardiovascular Disorders</i> , 2020, 20, 418.	0.7	5
158	Real-world evaluation of the impact of statin intensity on adherence and persistence to therapy: A Scottish population-based study. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 2349-2361.	1.1	16
159	Comparing effectiveness of high-dose Atorvastatin and Rosuvastatin among patients undergone Percutaneous Coronary Interventions: A non-concurrent cohort study in India. <i>PLoS ONE</i> , 2020, 15, e0233230.	1.1	9
160	Comparative Lipid-Lowering/Increasing Efficacy of 7 Statins in Patients with Dyslipidemia, Cardiovascular Diseases, or Diabetes Mellitus: Systematic Review and Network Meta-Analyses of 50 Randomized Controlled Trials. <i>Cardiovascular Therapeutics</i> , 2020, 2020, 1-21.	1.1	29
161	Clinical Pharmacology of Statins: an Update. <i>Current Atherosclerosis Reports</i> , 2020, 22, 26.	2.0	31
162	Generating comparative evidence on new drugs and devices before approval. <i>Lancet, The</i> , 2020, 395, 986-997.	6.3	59
163	Alpha lipoic acid and vitamin E improve atorvastatin-induced mitochondrial dysfunctions in rats. <i>Mitochondrion</i> , 2020, 52, 83-88.	1.6	12
164	Statins and muscle pain. <i>Expert Review of Clinical Pharmacology</i> , 2020, 13, 299-310.	1.3	21
165	CINeMA: An approach for assessing confidence in the results of a network meta-analysis. <i>PLoS Medicine</i> , 2020, 17, e1003082.	3.9	594
166	Effect of statin on semen quality characteristics. <i>Andrologia</i> , 2020, 52, e13592.	1.0	3
167	Current perceptions and practices in lipid management: results of a European Society of Cardiology/European Atherosclerosis Society Survey. <i>European Journal of Preventive Cardiology</i> , 2022, 28, 2030-2037.	0.8	8
168	Decoy Technology as a Promising Therapeutic Tool for Atherosclerosis. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4420.	1.8	5
169	In vivo evaluation of combination therapy targeting the isoprenoid biosynthetic pathway. <i>Pharmacological Research</i> , 2021, 167, 105528.	3.1	7
170	Intensity of statin therapy and muscle symptoms: a network meta-analysis of 153 000 patients. <i>BMJ Open</i> , 2021, 11, e043714.	0.8	14
171	Investigating raised creatine kinase. <i>BMJ, The</i> , 2021, 373, n1486.	3.0	3

#	ARTICLE	IF	CITATIONS
172	Cardiovascular Outcomes and Mortality Associated With Discontinuing Statins in Older Patients Receiving Polypharmacy. <i>JAMA Network Open</i> , 2021, 4, e2113186.	2.8	43
173	Hepatotoxicity Induced by Fluvastatin: A Reversible Acute Cholestatic Liver Injury. <i>American Journal of Case Reports</i> , 2021, 22, e931418.	0.3	4
174	A large remaining potential in lipid-lowering drug treatment in the type 2 diabetes population: A Danish nationwide cohort study. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 2354-2363.	2.2	2
175	Associations between statins and adverse events in primary prevention of cardiovascular disease: systematic review with pairwise, network, and dose-response meta-analyses. <i>BMJ, The</i> , 2021, 374, n1537.	3.0	88
176	Targeting nutrient metabolism with FDA-approved drugs for cancer chemoprevention: Drugs and mechanisms. <i>Cancer Letters</i> , 2021, 510, 1-12.	3.2	9
177	Statins™ Regulation of the Virulence Factors of <i>Helicobacter pylori</i> and the Production of ROS May Inhibit the Development of Gastric Cancer. <i>Antioxidants</i> , 2021, 10, 1293.	2.2	9
178	Balancing cardiovascular benefit and diabetogenic harm of therapy with statins: Real-world evidence from Italy. <i>Diabetes Research and Clinical Practice</i> , 2020, 164, 108197.	1.1	3
180	An analysis of psychotherapies delivered online and in person for patients with chronic pain: protocol for a systematic review and network meta-analysis. <i>HRB Open Research</i> , 2019, 2, 25.	0.3	3
181	SLCO1B1 Polymorphisms and Statin-Induced Myopathy. <i>PLOS Currents</i> , 2013, 5, .	1.4	36
182	Strategies for Primary Prevention of Coronary Heart Disease Based on Risk Stratification by the ACC/AHA Lipid Guidelines, ATP III Guidelines, Coronary Calcium Scoring, and C-Reactive Protein, and a Global Treat-All Strategy: A Comparative-Effectiveness Modeling Study. <i>PLoS ONE</i> , 2015, 10, e0138092.	1.1	32
183	Pravastatin activates activator protein 2 alpha to augment the angiotensin II-induced abdominal aortic aneurysms. <i>Oncotarget</i> , 2017, 8, 14294-14305.	0.8	13
184	Patterns and Predictors of Adherence to Statin Therapy Among Older Patients: Protocol for a Systematic Review. <i>JMIR Research Protocols</i> , 2017, 6, e39.	0.5	4
185	Optimal strategies for monitoring lipid levels in patients at risk or with cardiovascular disease: a systematic review with statistical and cost-effectiveness modelling. <i>Health Technology Assessment</i> , 2015, 19, 1-402.	1.3	30
186	Statin-Induced Changes in Mitochondrial Respiration in Blood Platelets in Rats and Human With Dyslipidemia. <i>Physiological Research</i> , 2016, 65, 777-788.	0.4	21
188	Statin therapy and lipoprotein(a) levels: a systematic review and meta-analysis. <i>European Journal of Preventive Cardiology</i> , 2022, 29, 779-792.	0.8	47
189	Statins Cardiovascular Benefits Outweigh their Diabetogenicity: A Direct Comparison between Number Needed to Treat and Number Needed to Harm. <i>Advances in Pharmacoepidemiology & Drug Safety</i> , 2015, 4, .	0.1	1
190	The Effects of Hydroalcoholic Borage Extract on Serum Lipid Profile in Mice and Comparison with Lovastatin. <i>Majallah-i Dānishgāh-i Ārshād-i Pizishk-i Ālām</i> , 2016, 24, 1-9.	0.1	0
192	Infográficos para decisão compartilhada no uso de estatinas em paciente de alto risco cardiovascular. <i>Revista Brasileira De Medicina De Família E Comunidade</i> , 2019, 14, 1809.	0.1	0

#	ARTICLE	IF	CITATIONS
194	Analysis of Safety Issues of Using Statins in Patients with Diabetes and Hypothyroidism. Safety and Risk of Pharmacotherapy, 2019, 7, 163-175.	0.1	1
195	EURASIAN ASSOCIATION OF CARDIOLOGY (EAC)/ RUSSIAN NATIONAL ATHEROSCLEROSIS SOCIETY (RNAS,) Tj ETQq1 1 0.784314 rgBT TREATMENT OF ATHEROSCLEROSIS (2020). Eurasian Heart Journal, 2020, , 6-29.	0.2	28
196	The relative effectiveness of psychotherapeutic techniques and delivery modalities for chronic pain: a protocol for a systematic review and network meta-analysis.. HRB Open Research, 2019, 2, 25.	0.3	1
197	Statin-Associated Myopathy: Emphasis on Mechanisms and Targeted Therapy. International Journal of Molecular Sciences, 2021, 22, 11687.	1.8	44
198	Which statin has the lowest risk of myalgia?. Evidence-Based Practice, 2020, 23, 47-48.	0.0	0
199	Medical Management of Atherosclerotic Carotid Disease. , 2020, , 59-68.		0
200	The rise of the statins and the burdening inefficiencies in liver monitoring. BJGP Open, 2020, 4, bjgpopen20X101066.	0.9	1
202	Statin-prescribing trends for primary and secondary prevention of cardiovascular disease. Canadian Family Physician, 2017, 63, e495-e503.	0.1	18
203	Yellow Yeast Rice Prepared Using Aspergillus terreus DSMK01 Lowers Cholesterol Levels by Stimulating Bile Salt Export Pump in Subjects with Mild to Moderate Hypercholesterolemia: A Randomized Controlled Trial. Molecular Nutrition and Food Research, 2021, , 2100704.	1.5	1
204	Race and Drug Toxicity: A Study of Three Cardiovascular Drugs with Strong Pharmacogenetic Recommendations. Journal of Personalized Medicine, 2021, 11, 1226.	1.1	3
205	Statin-associated side effects in patients attending a lipid clinic: evidence from a 6-year study. Archives of Medical Sciences Atherosclerotic Diseases, 2021, 6, 182-187.	0.5	0
206	The safety and efficacy of Ezetimibe Plus Statins on ASVD and Related Diseases. , 2021, 12, 1857.		2
207	In Vitro Antilipidic and Antithrombotic Activities of Plectranthus glandulosus (Lamiaceae) Leaves Extracts and Fractions. BioMed Research International, 2022, 2022, 1-14.	0.9	2
208	Detection and characterization of simvastatin and its metabolites in rat tissues and biological fluids using MALDI high resolution mass spectrometry approach. Scientific Reports, 2022, 12, 4757.	1.6	3
209	Side effects of statins: from pathophysiology and epidemiology to diagnostic and therapeutic implications. Cardiovascular Research, 2023, 118, 3288-3304.	1.8	57
211	Comparative effectiveness of statins on non-high density lipoprotein cholesterol in people with diabetes and at risk of cardiovascular disease: systematic review and network meta-analysis. BMJ, The, 2022, 376, e067731.	3.0	14
212	A comprehensive assessment of statin discontinuation among patients who concurrently initiate statins and CYP3A4 inhibitor drugs; a multistate transition model. British Journal of Clinical Pharmacology, 2022, , .	1.1	0
213	Neuroprotection in Acute Ischemic Stroke: A Battle Against the Biology of Nature. Frontiers in Neurology, 0, 13, .	1.1	19

#	ARTICLE	IF	CITATIONS
214	Association of Rosuvastatin Use with Risk of Hematuria and Proteinuria. <i>Journal of the American Society of Nephrology: JASN</i> , 2022, 33, 1767-1777.	3.0	9
215	Emodin lows NPC1L1-mediated cholesterol absorption as an uncompetitive inhibitor. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2022, 75, 128974.	1.0	2
216	Effectiveness and safety of proprotein convertase subtilisin/kexin type 9 inhibitors in patients with familial hypercholesterolemia. Our experience in implementing the drug program of the Polish National Health Fund. <i>Postępy W Kardiologii Interwencyjnej</i> , 2022, 18, 162-166.	0.1	0
217	Assessing the Incidence of New-onset Diabetes Mellitus with Statin Use: A Systematic Review of the Systematic Reviews and Meta-analyses. <i>European Endocrinology</i> , 2022, 18, 96.	0.8	3
219	Simvastatin: In Vitro Metabolic Profiling of a Potent Competitive HMG-CoA Reductase Inhibitor. <i>Separations</i> , 2022, 9, 400.	1.1	1
220	Comparative Muscle Tolerability of Different Types and Intensities of Statins: A Network Meta-Analysis of Double-Blind Randomized Controlled Trials. <i>Cardiovascular Drugs and Therapy</i> , 0, , .	1.3	1
221	Imaging subclinical coronary atherosclerosis to guide lipid management, are we there yet?. <i>American Journal of Preventive Cardiology</i> , 2023, 13, 100451.	1.3	1
222	Análise de aspectos sociodemográficos e clinicopatológicos em pacientes com Doença Arterial Coronariana e controles saudáveis. <i>Brazilian Journal of Development</i> , 2023, 9, 5157-5171.	0.0	0
223	Advanced therapeutics for targeting atherosclerosis. , 2023, , 93-105.		0
224	Generic versus brand-name cardiovascular drugs: a remarkable update. , 2022, 12, .		0
227	Statin Intolerance: An Overview for Clinicians. <i>Contemporary Diabetes</i> , 2023, , 597-635.	0.0	1